Xinmin Simon Xie
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$9.5MFederal grants as PI15 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
15 awards · $9.5M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Jul 31, 2025 | NIH | SBIR Phase II Accelerating the non-opioid analgesic AFA-281 clinical development with TABA-supported business development | $50K | AFASCI, INC. |
| Aug 27, 2024 | NIH | SBIR Phase II Clinical Phase I trials on an IND single molecule dual inhibitor of Cav3 channels and soluble epoxide hydrolase for treatment of neuropathic pain | $1.5M | AFASCI, INC. |
| Sep 7, 2023 | NIH | SBIR Phase II Clinical Phase I trials on an IND single molecule dual inhibitor of Cav3 channels and soluble epoxide hydrolase for treatment of neuropathic pain | $1.5M | AFASCI, INC. |
| Aug 20, 2020 | NIH | SBIR Phase II IND-enabling studies on novel Cav3 T-channel modulators for treatment of neuropathic pain | $1.5M | AFASCI, INC. |
| Jul 9, 2020 | NIH | SBIR Phase II Development of a Next Generation Visual Performance Assessment System for Rodents | $692K | AFASCI, INC. |
| Jul 15, 2019 | NIH | SBIR Phase I Discovering GIRK Channel Direct Activator as a Novel Chronic Insomnia Therapeutic | $100K | AFASCI, INC. |
| Jul 11, 2019 | NIH | SBIR Phase I Discovering GIRK Channel Direct Activator as a Novel Chronic Insomnia Therapeutic | $150K | AFASCI, INC. |
| Apr 23, 2019 | NIH | SBIR Phase II Development of a Next Generation Visual Performance Assessment System for Rodents | $788K | AFASCI, INC. |
| Sep 20, 2018 | NIH | SBIR Phase II Development of patented tricyclic pyrones molecules for the treatment of Alzheimer’s Disease | $241K | AFASCI, INC. |
| Sep 17, 2018 | NIH | SBIR Phase I Discovering GIRK Channel Direct Activator as a Novel Chronic Insomnia Therapeutic | $150K | AFASCI, INC. |
| Feb 12, 2018 | NIH | SBIR Phase II Development of patented tricyclic pyrones molecules for the treatment of Alzheimer’s Disease | $961K | AFASCI, INC. |
| Aug 10, 2016 | NIH | STTR Phase I Sample-free onsite detection of cocaine using microneedles via laser-treated skin | $224K | AFASCI, INC. |
| Jul 27, 2016 | NIH | SBIR Phase II Development of selective Cav3 channel blockers for treatment of neuropathic pain | $742K | AFASCI, INC. |
| Sep 10, 2015 | NIH | SBIR Phase II Development of selective Cav3 channel blockers for treatment of neuropathic pain | $691K | AFASCI, INC. |
| Aug 6, 2015 | NIH | STTR Phase I A Visual Assessment System for Retinal Function/Drug Discovery | $233K | AFASCI, INC. |
Peer ranks
Federal funding#69
Awards as PI#46
Patents#273
Companies
- AFASCI, INC.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.